Antioxidant polymer nanoparticles ameliorate cancer cachexia via intestinal ROS scavenging.

Area of Science:

• Oncology
• Gastroenterology
• Nanomedicine

Background:

• Cancer cachexia impacts 80% of advanced cancer patients, causing anorexia, weight loss, and muscle wasting, significantly reducing survival.
• Current therapeutic options for cancer cachexia are limited, despite its profound clinical impact.
• Interleukin-6 (IL-6), a key inflammatory cytokine, is implicated in cachexia pathogenesis, presenting a potential therapeutic target.

Purpose of the Study:

• To investigate the role of intestinal oxidative stress in systemic inflammation driving cancer cachexia.
• To evaluate the efficacy of orally administered antioxidant nanoparticles (siSMAPo^TN) in a mouse model of cancer cachexia.

Main Methods:

• Tumor-bearing mice modeling cancer cachexia were treated with siSMAPo^TN, designed for intestinal localization and reactive oxygen species (ROS) scavenging.
• Measurements included plasma IL-6 levels, muscle protein degradation signaling pathways, and muscle atrophy.

Main Results:

• siSMAPo^TN treatment effectively suppressed elevated plasma IL-6 levels.
• The nanoparticles mitigated muscle protein degradation signaling pathways.
• Muscle atrophy was significantly prevented, demonstrating systemic therapeutic effects from localized intestinal action.

Conclusions:

• Increased intestinal oxidative stress contributes to the systemic inflammatory cascade observed in cancer cachexia.
• Intestinally acting antioxidant nanoparticles represent a novel, non-invasive therapeutic strategy for managing cancer cachexia.
• siSMAPo^TN demonstrates significant potential for alleviating cancer cachexia by targeting gut-derived inflammation.